sph4336
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Nov 3, 2020 (NCT05905614)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05944224 | Phase 1/Phase 2 (Phase 2) | Oct 17, 2023 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT05872347 | Phase 2 | Sep 19, 2023 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT05860465 | Phase 2/Phase 3 (Phase 3) | Sep 8, 2023 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT05744687 | Phase 2/Phase 3 (Phase 3) | Apr 24, 2023 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT05580588 | Phase 2 | Dec 31, 2022 | — |
| NCT05905614 | Phase 1/Phase 2 (Phase 2) | Nov 3, 2020 | Shanghai Pharmaceuticals Holding Co., Ltd |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Pharmaceuticals Holding Co., Ltd | For profit | 5 | 5 | 2 | 2020 |
1 organizations
Page 1 / 1